BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GlaxoSmithKline (GSK) Awarded Funds to Advance Dermal Treatment with Starpharma Pty Limited (SPL.AX)'s Dendrimers


8/22/2011 10:41:51 AM

August 22, 2011 -- GlaxoSmithKline (GSK), and Starpharma (ASX:SPL, OTCQX:SPHRY) today announced that GSK was awarded a grant to advance a dermal treatment based on Starpharma’s dendrimer drug delivery technology.

The funds will be used to support Starpharma’s synthesis of dendrimer-based drug candidates which will then be tested by Stiefel, a GSK company with a view to further development towards a dermal product.

The funding has been provided under a grant program run by the Victorian Government.

Dr Jackie Fairley, CEO Starpharma said “We are very pleased to have this opportunity to further develop our valued relationship with GSK through their dermatology business Stiefel. We remain extremely upbeat about the value of dendrimers for a wide range of drug delivery applications and look forward to working with Stiefel to apply our technology to dermal applications.”

Ms Deborah Waterhouse, General Manager GSK Aus & NZ said “The partnership with Starpharma is an exciting step forward for Stiefel, which is committed to innovation in dermatology leading to new medicines for patients.”

Starpharma’s dendrimers are a type of precisely-defined, branched nanoparticle. In pharmaceuticals dendrimers have applications in enhancing drug half-life, solublising drugs, and targeting drugs to specific destinations in the body. More widely dendrimers have applications in medical, electronics, chemicals and materials industries.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES